- Trial phase
- Approved
- Time to market
- Already FDA-approved and commercially marketed
- Why 4/10
- CYTOGAM is already FDA-approved and marketed with no pending regulatory decision or pivotal readout within the next ~12 months. The SHIELD post-marketing study (NCT07009548) has a primary completion date of December 2027. The ISHLT data presentation in July 2026 was a routine scientific communication, not a binary catalyst. ImpactScore 4 reflects a mature commercial product with steady but non-catalytic growth.
CYTOGAM contributes ~12-13% of Kamada's total revenue (~$22.5M in 2024) and is growing 31% YoY, but is not a binary catalyst for the stock. Watch Q2 2026 earnings (~Aug 12, 2026) for CYTOGAM sales trajectory and any updates on the SHIELD study. The stock's primary drivers are Glassia (alpha-1 antitrypsin) and KEDRAB (rabies IG), which represent larger revenue streams.
Price Chart
Executive Summary
CYTOGAM is an FDA-approved, commercially marketed intravenous hyperimmune globulin used to prevent cytomegalovirus disease in solid organ transplant recipients. It is the sole FDA-approved CMV hyperimmune globulin for this indication. Kamada acquired the product from CSL Behring in 2021 and now manufactures it in-house (FDA-approved 2023). CYTOGAM generated ~$22.5M in revenue for Kamada in 2024 (~12-13% of total revenue), growing 31% year-over-year. The drug has no imminent binary catalyst, the SHIELD post-marketing study won't read out before 2028, and the recent ISHLT data presentation was supportive but routine. Kamada's stock is more meaningfully driven by its larger products (KEDRAB rabies IG at ~$50M, Glassia alpha-1 at a larger share) and overall 2026 revenue guidance of $200-205M.
How It Works
CYTOGAM is a purified blood product (hyperimmune globulin) rich in antibodies that specifically neutralize cytomegalovirus (CMV). It is injected intravenously into transplant patients to help prevent CMV infection, working outside the body's cells by neutralizing the virus before it can infect cells. It is typically used alongside standard antiviral drugs (like valganciclovir or ganciclovir) that work inside the cells, providing complementary, dual-mode protection.
Trial Status
CYTOGAM has been FDA-approved since the 1990s (originally by CSL Behring/MedImmune). Kamada acquired it in November 2021 and received FDA approval to manufacture it at its own Israel facility in May 2023. A post-marketing investigator-initiated study (SHIELD, NCT07009548) enrolled its first patient in November 2025, testing CYTOGAM to prevent late CMV in high-risk kidney transplant recipients, with primary completion estimated December 2027. Additional retrospective lung-transplant data from 324 patients was presented at the ISHLT 2026 annual meeting in Toronto (July 2026), showing CMV high-risk recipients not receiving CMVIG had worse outcomes.
The Two-Sided Case
Upcoming Catalysts
- Q2 2026 earnings call (~August 12, 2026), CYTOGAM sales update and full-year 2026 guidance tracking
- Full publication of ISHLT 2026 retrospective lung-transplant data expected later in 2026
- SHIELD study (NCT07009548) enrollment updates, but primary completion not until December 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
KAMADA LTD 6-K KMDA ·Originating report